Cancer experts warn of burden on poor countries as death rates soar
The world faces a rapidly growing burden of cancer, which will overwhelm governments unless the medical and pharmaceuticals industry takes the lead on a multibillion-dollar, private-public fund, say oncologists.
In a report on how global rates of cancer diagnosis and death are rising while access to diagnosis and treatment is extremely patchy, experts described the economics of the problem as daunting and current financing models as broken.
"It is bad to have cancer, and worse to have cancer if you are poor," said Professor Peter Boyle of France's International Prevention Research Institute, a lead author on the State of Oncology 2013 report.
"Many parts of the world are already unable to cope with the current situation and are totally unprepared for the future growth of the cancer problem," he told a briefing during the European Cancer Congress in Amsterdam.
Boyle, director of the Institute of Global Public Health at Strathclyde University, cited estimates from 2009 by the Economist Intelligence Unit that it would cost $217bn (£135bn) a year to bring cancer diagnosis, care and treatment in poor countries up to the standards of rich nations.
"There's no single source of philanthropy, there's no government, there's no company, there's no single institution that can afford that sort of investment," he said. "The current model of financing is broke. We need to fix it. We need radical solutions."
According to the International Agency for Research on Cancer, the disease will kill more than 13.2 million people a year by 2030, almost double the number in 2008. The vast majority of deaths will be in low- and middle-income countries.
In poorer countries, Boyle said, where equipment, expertise and medicines for cancer were scarce and sometimes non-existent, the increasing burden of the disease threatened to cause devastating damage to entire families.
Boyle's report projected that with growing and ageing populations in some of the world's most populous countries, such as India, China and Nigeria, as well as changing diets and lifestyles, the number of cases of cancer worldwide would reach 26.4m a year by 2030 and the annual death toll would be close to 17 million.
"It is impossible to avoid the conclusion that there is a need for a major public-private partnership, involving a number of sources from different areas, to make the necessary progress with the briefest delay," Boyle said.
He added that such a partnership needed the commitment of the drug companies, as well as industries involved in diagnostic and treatment technology such as scanning and radiotherapy equipment.
Asked how he envisaged such a fund working, Boyle pointed to the Global Fund to Fight AIDS, Tuberculosis and Malaria, a public-private partnership set up in 2002, which has made impressive progress in tackling epidemics of the three deadly infectious diseases.
The Global Fund, which gets most of its money from OECD governments, this month said it needed a further $15bn to support another three years of work. Yet the money and commitment needed to tackle cancer would far outstrip the Global Fund's size, Boyle pointed out. He advocated a new industry-led approach committed not only to giving funds, but donating knowledge, medicines, equipment and training.